# IFM Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ifm-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.ifmthera.com
- Total disclosed funding: $27M
- Latest round: Series A (Jun 22, 2016)
- Investors on record: 3

## About

Based in Massachusetts, US, and founded in 2015 and led by CEO H. Martin Seidel, IFM Therapeutics, LLC operates as a biopharmaceutical company that develops small molecules that modulate novel targets in the innate immune system for cancer, autoimmunity and inflammatory treatment. In March 2024, Novartis International AG acquired IFM Therapeutics, LLC for an initial USD 835 million, with an upfront payment of USD 90 million, and will receive approximately USD 745 million upon achieving milestones through 2024.

IFM Therapeutics, LLC developed small molecule drugs that modulate the innate immune system. The company’s portfolio includes NLRP3 antagonists, STING antagonists, and cGAS inhibitors, targeting conditions such as chronic inflammatory and fibrotic disorders, inflammatory bowel disease, neuroinflammation, and cancer. In addition, the firm focuses on improving the lives of patients with inflammation-driven diseases and cancer.

## Funding rounds

- Series A, Jun 22, 2016, $27M — Abingworth, Atlas Venture, Novartis

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A
- Novartis — Series A